fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Fluphenazine HCL

All products: general benefit

Fluphenazine · DIN 00405345 · 1 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Fluphenazine · DIN 00405345 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2012-07-10 · brand FLUPHENAZINE · ATC N05AB02 FLUPHENAZINE · form Tablet · route Oral · ingredients FLUPHENAZINE HYDROCHLORIDE 1 MG · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Fluphenazine: Formulary list price $0.17 per unit (the source does not state the unit; exact figure $0.1739). What the ministry pays, not the patient.

Ministry pays: $0.1739 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00405345)

Source record
DIN 00405345: Fluphenazine Raw flags: sec3=Y Item: 281608030; group id 491; item number 1255; lccId None; manufacturer id AAP Source form: Tab; strength: 1mg Recorded listing: General benefit Source prices (unrounded): $0.1739; ministry $0.1739 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00405345 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2858
Interchangeable products
Moditen HCL · DIN 00029378 · not recorded
Shortage status: resolved shortage (ended June 3, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00405345
Shortage record checked October 6, 2026

Other products in the same Health Canada class (N05A, N05AB): coverage varies; not interchangeable

  • Perphenazine (Trilafon): general benefit, not a benefit
  • Prochlorperazine (Prochlorazine): general benefit, not a benefit
  • Trifluoperazine: general benefit, not a benefit
  • Aripiprazole (Abilify Asimtufii): general benefit
  • Asenapine (Saphris): general benefit
  • Brexpiprazole (Rexulti): general benefit

18 more in the class list below

Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

PERPHENAZINE

· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 2mg, 4mg, 8mg, 16mg · Tab

PROCHLORPERAZINE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 5mg, 10mg · Tab

TRIFLUOPERAZINE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 1mg, 2mg, 5mg, 10mg · Tab

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab

FLUPENTIXOL DECANOATE

· 2 products · General benefit · strengths: 20mg/mL, 100mg/mL · Inj Sol-1mL Amp Pk

FLUPENTIXOL DIHYDROCHLORIDE

· 2 products · General benefit · strengths: 0.5mg, 3mg · Tab

HALOPERIDOL

· 14 products · Listed, not a benefit (7), General benefit (7) · strengths: 5mg/mL, 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg · Inj Sol-1mL Pk, Tab

LOXAPINE SUCCINATE

· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 5mg, 10mg, 25mg, 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:16:08 and 21 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: manifestations of psychotic disorders
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. PERPHENAZINE · Listed, not a benefit (4), General benefit (4) Indications PERPHENAZINE (perphenazine tablets) is indicated for: • Management of manifestations of psychotic disorders. PM: https://pdf.hres.ca/dpd_pm/00084763.PDF; date May 15, 2026; DIN 00335096; fetched 2026-09-10 Product monograph PROCHLORPERAZINE · General benefit (2), Listed, not a benefit (2) Indications PROCHLORAZINE (Prochlorperazine Maleate Tablets) is indicated for: • the management of manifestations of psychotic disorders such as agitation, confusion, delusion, tension and anxiety. PM: https://pdf.hres.ca/dpd_pm/00082835.PDF; date 2025-12-15; DIN 00886432; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS FLUPHENAZINE (fluphenazine hydrochloride) is indicated for: • Management of manifestations of psychotic disorders. • Treatment of behavioral disorders in adults. 1.1 Pediatrics Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of FLUPHENAZINE in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. See 7.1.3 Pediatrics and 8 ADVERSE REACTIONS. 1.2 Geriatrics Geriatrics (>60 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. See 3 SERIOUS WARNINGS AND PRECAUTIONS BOX; 4.2 Recommended Dose and Dosage Adjustment and 7.1.4 Geriatrics. https://pdf.hres.ca/dpd_pm/00069653.PDF PM date: DEC 31, 1977 Source product: FLUPHENAZINE; DIN 00405345; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.